Clinical trialNCT04782609TerminatedPhase 1Interventional

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma

SponsorSamus Therapeutics, Inc.Enrollment7Glioblastoma SurgeryGrade 3 Isocitrate Dehydrogenase (IDH) Wildtype AstrocytomaGrade 3 or 4 AstrocytomaRecurrent Glioblastoma Multiforme (GBM)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a 2-part multicenter Phase 1b study designed to test icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation design where different doses are examined. Part 2 will be a dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D). The RP2D is defined as the dose level recommended for further clinical study, or the highest dose tested.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Michael Silverman, MD
Samus Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, Las Angeles Medical Center
Los Angeles, California, United States
University of California San Diego
San Diego, California, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Md Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Icapamespib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Dec 2021
Primary completion: 4 Nov 2022
Completion: 4 Nov 2022
Last update posted: 17 Nov 2022
Registered enrollment: 7
Registry id: NCT04782609

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.